SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biomatrix (BXM) Looking Great
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: lwd who wrote (528)9/23/1999 9:26:00 AM
From: SC  Read Replies (1) of 569
 
As I read it, the CEO said they are waiting for official release of the data but obviously he wanted it to be known as a good news. He probably has his reasons for not giving more details before the independent researchers do for their own work. He said:

"We look forward to the release of full trial results from this landmark study in the peer reviewed literature. This data will demonstrate the value of Synvisc and will be important to patients and healthcare providers."

This recently completed trial was designed, managed and reported by an independent academic steering committee of international opinion leaders in compliance with published guidelines for pharmacoeconomic studies. Fourteen clinical investigators, specialists in both rheumatology and orthopedics, conducted the study over the past two years with patients from all across Canada.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News